Introduction Current guidelines recommend cardiac resynchronisation therapy (CRT) in patients with severe symptomatic heart failure, depressed left ventricular (LV) systolic function and a wide QRS complex (≥120 ms). However, patients with heart failure having a narrow QRS complex might also benefit from CRT.
Design setting patients interventions During the Predictors of Response to Cardiac Resynchronisation Therapy (PROSPECT) trial, 41 patients were enrolled in a ‘narrow’ QRS sub-study. These patients had a QRS complex <130 ms, but documented evidence of mechanical dyssynchrony by any of seven pre-defined echocardiographic measures.
Results After 6 months of CRT, 26 (63.4%) patients showed improvement according to the Clinical Composite Score, 4 (9.8%) remained unchanged and 11 (26.8%) worsened. In patients with paired data, the 6-min walking distance increased from 334±118 m to 382±128 m, (p=0.003) and quality-of-life score improved from 44.2±19.7 to 26.8±20.2 (p<0.0001). Furthermore, there was a significant decrease in LV end-systolic diameter (from 59±9 to 55±12 mm, p=0.002) and in LV end-diastolic diameter (from 67±9 to 63±11 mm, p=0.007).
Conclusion The results suggest that CRT may have a beneficial effect in heart failure patients with a narrow QRS complex and mechanical dyssynchrony as assessed by echocardiography. The majority of patients improved on clinical symptoms, and there was an evident reduction in LV diameters. Larger studies are needed to clearly define selection criteria for CRT in patients with a narrow QRS complex.
- cardiac remodelling
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Funding Medtronic Inc. provided funding for this study and manufactured the CRT system used in this research. Other Funders: NIH.
Competing interests John Gorcsan III: received grants from NIH award K24 HL04503-01, and from GE Healthcare, Medtronic, St Jude Medical and Biotronik.
Eugene S. Chung: received research support from Medtronic; consultant for Medtronic, Boston Scientific, St Jude Medical; speaker for Medtronic, Boston scientific.
William T. Abraham: consulting fees from Medtronic.
Christophe Leclercq: research grants from Medtronic, St. Jude Medical, Biotronik, Boston Scientific and Sorin Ela.
Mark J. Monaghan: research support from Medtronic, Philips, Siemens, GE Healthcare, TomTec; Speaker's bureau for Philips, Siemens.
Petros Nihoyannopoulos: research grant from Medtronic.
Cheuk-Man Yu: research grant from Medtronic, speaker for Medtronic, Boston Scientific, St Jude Medical, Philips and GE Healthcare.
Myriam Demas: employee of Medtronic.
Bart Gerritse: employee of Medtronic.
Jeroen J. Bax: received grants from Medtronic, Boston Scientific, BMS medical imaging, St. Jude Medical, Edwards Life sciences & GE Healthcare.
Ethics approval This study was conducted with the approval of the Ethical Committee of each participating centre.
Provenance and peer review Not commissioned; externally peer reviewed.